The Werfen initiative highlights the clinical role of diagnostics in patient care as the medical company marks 60 years.



RT’s Three Key Takeaways:

  1. Diagnostic Decision Impact: In vitro diagnostics (IVD) influences approximately 70% of clinical decisions globally, ranging from monitoring during complex cardiac surgery to managing chronic conditions.
  2. Patient-Focused Initiative: Werfen launched the “Thank You” campaign, centered on a documentary short film that features real patient stories to recognize the behind-the-scenes contributions of laboratory professionals and clinicians.
  3. Six-Decade Milestone: The anniversary effort coincides with the company’s 60-year milestone and follows an investment of 190 million euros dedicated to research and development (R&D) in 2025.


Specialized diagnostics company Werfen has launched its “Thank You” campaign to honor healthcare professionals and clinical laboratory teams for their vital contributions to medical decision-making and patient outcomes, according to the company.

Timed to mark the Barcelona-based manufacturer’s 60th anniversary, the initiative serves as the organization’s first corporate brand campaign focused on its mission of supporting patient care through specialized testing solutions, the company stated.

In vitro diagnostics (IVD) currently guides roughly 70% of medical decisions worldwide, according to the company. These analytical procedures inform care paths in severe clinical circumstances, including patient monitoring during complex cardiac surgery, evaluating chronic disease, and verifying organ compatibility during kidney and liver transplants, Werfen reported. Despite this clinical importance, the company noted that much of this diagnostic work occurs behind the scenes.

Patient Perspectives on Diagnostic Precision

The centerpiece of the campaign is a documentary short film that highlights the clinical necessity of dependable, rapid data during both immediate diagnosis and long-term disease management.

Created alongside patient advocacy groups and non-profit organizations, the project features accounts from individuals who navigated serious medical challenges, the release noted. Patients in the film share their appreciation for the laboratory personnel and clinicians who evaluated test results to guide their care across conditions such as thrombosis events, lupus, hemophilia, rheumatoid arthritis, and organ transplantation, according to Werfen.

“Sixty years ago, Werfen was born with a calling to stand alongside healthcare professionals in moments that mark a before and after in patients’ lives. Our responsibility is to provide maximum analytical precision so that professionals can make decisions with total confidence when it matters most,” said Alejandro Risso, CEO of Werfen.

“Behind every diagnosis there is knowledge, experience, precision and, above all, people committed to improving and saving lives. With this campaign we want to bring these professionals to the forefront and thank them for a work that, after 60 years, continues to give meaning to ours,” said Risso.

Focus on Specialized Clinical Diagnostics

The effort represents Werfen’s five core diagnostic business areas: Hemostasis, Acute Care Diagnostics, Transfusion, Autoimmunity, and Transplant.

Established in 1966, the company expanded operations internationally into major markets including the US and China, according to the release. Werfen strategically shifted in 2024 to dedicate its research, resources, and operational assets exclusively to IVD.

To maintain technical progress in laboratory and critical care testing, Werfen directed 190 million euros toward research and development (R&D) in 2025.